# Coramaze Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/coramaze-technologies

- Industry: Medical Devices & Equipment
- Headquarters: Essen, Germany
- Website: www.coramaze.com
- Total disclosed funding: $6.5M
- Latest round: Series A (Jun 18, 2015)
- Investors on record: 3

## About

Coramaze Technologies GmbH is a medical technology company focused on developing innovative solutions for tricuspid valve repair. Its flagship product, Tripair™, is designed to address heart valve conditions through minimally invasive procedures.Founded in 2013 and headquartered in Essen, Germany, Coramaze Technologies GmbH specializes in tricuspid valve repair solutions. The company has completed a total of 3 deals, with the most recent funding round occurring on March 23, 2017, during which it raised EUR 4.50 mn in a Series A round led by Elron Ventures. Jochen Reinöhl serves as the CEO of the company.Tripair™ is the flagship product of Coramaze, a pioneering tricuspid valve repair system designed to address the significant challenges posed by tricuspid regurgitation (TR). This investigational device aims to provide a simple, safe, and effective solution for TR, a heart valve condition that impacts millions globally and is often left untreated. Tripair™ functions by providing a minimally invasive alternative to traditional surgical interventions, making it a viable option for a broader patient population, including those who are typically ineligible for surgery. The device is intended to simplify the treatment process, making it accessible for interventionalists to perform with ease, akin to a right heart catheterization. Coramaze targets markets in Europe and the United States, focusing on regions with high incidences of severe TR, contributing to improved health equity for patients affected by this condition.The revenue model for Coramaze is centered around the commercialization of its investigational device, Tripair™, which is currently not available for purchase. The company is expected to engage in business-to-business (B2B) transactions with healthcare providers, hospitals, and clinics specializing in interventional cardiology, facilitating partnerships that enable these institutions to offer innovative TR treatment solutions to their patients. Revenue generation would typically occur upon the successful regulatory approval and subsequent market launch of Tripair™, where healthcare facilities would procure the device based on their patient needs and treatment protocols. Pricing structures will be established post-approval, tailored to align with the healthcare system’s reimbursement frameworks, potentially involving direct sales or strategic partnerships with medical device distributors to enhance market penetration.Coramaze Technologies GmbH aims to leverage its recent funding round to accelerate the development and regulatory approval of Tripair™, with plans to expand its presence in the European and U.S. markets by targeting hospitals and clinics specializing in interventional cardiology. The recent funding will support further product development and market entry strategies, which are crucial for addressing the unmet needs in TR treatment. The company is strategically positioned to advance these initiatives, aiming for market launch upon successful regulatory clearance.

## Funding rounds

- Series A, Jun 18, 2015, $5.1M — High-Tech Gruenderfonds, S-Venture Capital Dortmund, Elron Ventures
- Seed, Feb 6, 2014, $1.4M — High-Tech Gruenderfonds, S-Venture Capital Dortmund

## Investors

- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed, Series A
- S-Venture Capital Dortmund (https://capitalatlas.ai/funds/s-venture-capital-dortmund) — Seed, Series A
- Elron Ventures (https://capitalatlas.ai/funds/elron-ventures) — Series A